Karen Whitmarsh

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 456 citations · Full text

Medicine, Gynecology, Oncology +17

Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience

Arthur Sun Myint, F. M. Smith, Simon Gollins et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 85 citations

Medicine, Oncology, Radiation Oncology +14

Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?

Arthur Sun Myint, F. M. Smith, Simon Gollins et al. · British Journal of Radiology · 2017 · 57 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Cathalijne Post, Stephanie M. de Boer, Melanie Powell et al. · The Lancet Oncology · 2025 · 29 citations · Full text

Medicine, Gynecology, Oncology +17